Dr Olsen is a medical oncologist with 20 years of experience in drug and diagnostics development and medical affairs. He received a BS in Biological Sciences from Stanford University, an MD from Oregon Health and Science University, and a PhD in Cellular and Molecular Biology from the University of Michigan. He completed post-graduate training at the University of California, San Diego, and at the University of California, San Francisco.
He has held various positions of increasing responsibility at Sanofi, Genentech, and AstraZeneca. He led global development on medical strategy for anti-cancer medicines such as Taxotere, Kadcyla, Faslodex, Lynparza, and Tagrisso.